Patents Assigned to Applied Immune Technologies
  • Immunogens for treatment of neoplastic and infectious disease
    Patent number: 8969012
    Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: March 3, 2015
    Assignee: Applied Immune Technologies
    Inventor: Raj Tiwari
  • Immunogens for treatment of neoplastic and infectious disease
    Patent number: 8088569
    Abstract: The present invention relates to prophylactic and therapeutic methods of immunization against neoplastic and infectious diseases. The invention provides a method for identification of novel immunogens and compositions of such immunogens that are useful for eliciting immune responses against antigens associated with neoplastic or infectious diseases.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: January 3, 2012
    Assignee: Applied Immune Technologies
    Inventor: Raj Tiwari
  • Immunotherapy for prostate cancer using recombinant bacille Calmette-Guerin expressing prostate specific antigens
    Patent number: 7718166
    Abstract: The present invention relates to the treatment of prostate cancer. Methods and compositions comprising recombinant BCG are provided for eliciting potent immune responses against prostate specific antigens that are effective for treatment of prostate cancer and metastatic disease.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: May 18, 2010
    Assignee: Applied Immune Technologies
    Inventor: Jan Geliebter
  • Antigens
    Publication number: 20070111261
    Abstract: The invention provides a method for identifying amino acid sequences in antigens of interest that are useful for evoking immune responses. The amino acid sequences have low sequence similarity to the host proteome and are predicted to bind to MHC. Also disclosed are HPV epitopes that evoke Class I or Class II mediated immune responses.
    Type: Application
    Filed: December 6, 2006
    Publication date: May 17, 2007
    Applicant: Applied Immune Technologies, Inc.
    Inventors: Abraham Mittelman, Darja Kanduc